Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned an average rating of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $44.71.

Several research firms have recently commented on DNTH. Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Wedbush cut their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a research report on Thursday, June 27th. They issued an “overweight” rating on the stock. Finally, Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective on the stock.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $27.85 on Wednesday. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The firm has a market cap of $817.37 million, a P/E ratio of -4.78 and a beta of 1.85. The firm has a 50-day simple moving average of $27.91 and a 200-day simple moving average of $26.19.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The business had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. On average, research analysts predict that Dianthus Therapeutics will post -2.32 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several large investors have recently bought and sold shares of DNTH. Vestal Point Capital LP purchased a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $1,404,000. Octagon Capital Advisors LP grew its position in Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after purchasing an additional 74,000 shares during the last quarter. Hussman Strategic Advisors Inc. purchased a new stake in Dianthus Therapeutics during the 1st quarter worth approximately $630,000. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Finally, StemPoint Capital LP purchased a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at $1,304,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.